A citation-based method for searching scientific literature

Kathleen M Schoch, Timothy M Miller. Neuron 2017
Times Cited: 126







List of co-cited articles
1264 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Richard S Finkel, Claudia A Chiriboga, Jiri Vajsar, John W Day, Jacqueline Montes, Darryl C De Vivo, Mason Yamashita, Frank Rigo, Gene Hung, Eugene Schneider,[...]. Lancet 2016
475
18

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.
Timothy M Miller, Alan Pestronk, William David, Jeffrey Rothstein, Ericka Simpson, Stanley H Appel, Patricia L Andres, Katy Mahoney, Peggy Allred, Katie Alexander,[...]. Lancet Neurol 2013
380
17

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Richard S Finkel, Eugenio Mercuri, Basil T Darras, Anne M Connolly, Nancy L Kuntz, Janbernd Kirschner, Claudia A Chiriboga, Kayoko Saito, Laurent Servais, Eduardo Tizzano,[...]. N Engl J Med 2017
708
17


Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Eugenio Mercuri, Basil T Darras, Claudia A Chiriboga, John W Day, Craig Campbell, Anne M Connolly, Susan T Iannaccone, Janbernd Kirschner, Nancy L Kuntz, Kayoko Saito,[...]. N Engl J Med 2018
476
16

Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice.
Lindsay A Becker, Brenda Huang, Gregor Bieri, Rosanna Ma, David A Knowles, Paymaan Jafar-Nejad, James Messing, Hong Joo Kim, Armand Soriano, Georg Auburger,[...]. Nature 2017
222
15

Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
Claudia A Chiriboga, Kathryn J Swoboda, Basil T Darras, Susan T Iannaccone, Jacqueline Montes, Darryl C De Vivo, Daniel A Norris, C Frank Bennett, Kathie M Bishop. Neurology 2016
318
15

Targeting Huntingtin Expression in Patients with Huntington's Disease.
Sarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, Edward J Wild, Carsten Saft, Roger A Barker, Nick F Blair, David Craufurd, Josef Priller, Hugh Rickards,[...]. N Engl J Med 2019
219
14

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.
Daniel R Scoles, Pratap Meera, Matthew D Schneider, Sharan Paul, Warunee Dansithong, Karla P Figueroa, Gene Hung, Frank Rigo, C Frank Bennett, Thomas S Otis,[...]. Nature 2017
140
13

Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.
Richard S Geary, Daniel Norris, Rosie Yu, C Frank Bennett. Adv Drug Deliv Rev 2015
370
12

Antisense oligonucleotide therapy for neurodegenerative disease.
Richard A Smith, Timothy M Miller, Koji Yamanaka, Brett P Monia, Thomas P Condon, Gene Hung, Christian S Lobsiger, Chris M Ward, Melissa McAlonis-Downes, Hongbing Wei,[...]. J Clin Invest 2006
308
12

Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs.
Jie Jiang, Qiang Zhu, Tania F Gendron, Shahram Saberi, Melissa McAlonis-Downes, Amanda Seelman, Jennifer E Stauffer, Paymaan Jafar-Nejad, Kevin Drenner, Derek Schulte,[...]. Neuron 2016
268
12

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.
Mariely DeJesus-Hernandez, Ian R Mackenzie, Bradley F Boeve, Adam L Boxer, Matt Baker, Nicola J Rutherford, Alexandra M Nicholson, NiCole A Finch, Heather Flynn, Jennifer Adamson,[...]. Neuron 2011
12


Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.
Holly B Kordasiewicz, Lisa M Stanek, Edward V Wancewicz, Curt Mazur, Melissa M McAlonis, Kimberly A Pytel, Jonathan W Artates, Andreas Weiss, Seng H Cheng, Lamya S Shihabuddin,[...]. Neuron 2012
437
11

Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.
Andrew C Elden, Hyung-Jun Kim, Michael P Hart, Alice S Chen-Plotkin, Brian S Johnson, Xiaodong Fang, Maria Armakola, Felix Geser, Robert Greene, Min Min Lu,[...]. Nature 2010
750
11

The delivery of therapeutic oligonucleotides.
Rudolph L Juliano. Nucleic Acids Res 2016
387
11

Antisense oligonucleotides in neurological disorders.
Claudia D Wurster, Albert C Ludolph. Ther Adv Neurol Disord 2018
60
18

Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
Marco A Passini, Jie Bu, Amy M Richards, Cathrine Kinnecom, S Pablo Sardi, Lisa M Stanek, Yimin Hua, Frank Rigo, John Matson, Gene Hung,[...]. Sci Transl Med 2011
319
11

Identification and characterization of a spinal muscular atrophy-determining gene.
S Lefebvre, L Bürglen, S Reboullet, O Clermont, P Burlet, L Viollet, B Benichou, C Cruaud, P Millasseau, M Zeviani. Cell 1995
11

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
Manuela Neumann, Deepak M Sampathu, Linda K Kwong, Adam C Truax, Matthew C Micsenyi, Thomas T Chou, Jennifer Bruce, Theresa Schuck, Murray Grossman, Christopher M Clark,[...]. Science 2006
11

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.
A Fire, S Xu, M K Montgomery, S A Kostas, S E Driver, C C Mello. Nature 1998
10

Pharmacology of Antisense Drugs.
C Frank Bennett, Brenda F Baker, Nguyen Pham, Eric Swayze, Richard S Geary. Annu Rev Pharmacol Toxicol 2017
174
10

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy.
Sarah L DeVos, Rebecca L Miller, Kathleen M Schoch, Brandon B Holmes, Carey S Kebodeaux, Amy J Wegener, Guo Chen, Tao Shen, Hien Tran, Brandon Nichols,[...]. Sci Transl Med 2017
168
10

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.
Alan E Renton, Elisa Majounie, Adrian Waite, Javier Simón-Sánchez, Sara Rollinson, J Raphael Gibbs, Jennifer C Schymick, Hannu Laaksovirta, John C van Swieten, Liisa Myllykangas,[...]. Neuron 2011
10

Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.
Yimin Hua, Kentaro Sahashi, Gene Hung, Frank Rigo, Marco A Passini, C Frank Bennett, Adrian R Krainer. Genes Dev 2010
383
10

Antisense oligonucleotides in therapy for neurodegenerative disorders.
Melvin M Evers, Lodewijk J A Toonen, Willeke M C van Roon-Mom. Adv Drug Deliv Rev 2015
160
9

Cellular uptake and trafficking of antisense oligonucleotides.
Stanley T Crooke, Shiyu Wang, Timothy A Vickers, Wen Shen, Xue-Hai Liang. Nat Biotechnol 2017
201
9

Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.
Caroline Vance, Boris Rogelj, Tibor Hortobágyi, Kurt J De Vos, Agnes Lumi Nishimura, Jemeen Sreedharan, Xun Hu, Bradley Smith, Deborah Ruddy, Paul Wright,[...]. Science 2009
9

RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention.
Christopher J Donnelly, Ping-Wu Zhang, Jacqueline T Pham, Aaron R Haeusler, Nipun A Mistry, Svetlana Vidensky, Elizabeth L Daley, Erin M Poth, Benjamin Hoover, Daniel M Fines,[...]. Neuron 2013
567
9

Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis.
T J Kwiatkowski, D A Bosco, A L Leclerc, E Tamrazian, C R Vanderburg, C Russ, A Davis, J Gilchrist, E J Kasarskis, T Munsat,[...]. Science 2009
9

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.
Jerry R Mendell, Samiah Al-Zaidy, Richard Shell, W Dave Arnold, Louise R Rodino-Klapac, Thomas W Prior, Linda Lowes, Lindsay Alfano, Katherine Berry, Kathleen Church,[...]. N Engl J Med 2017
772
9

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.
D R Rosen, T Siddique, D Patterson, D A Figlewicz, P Sapp, A Hentati, D Donaldson, J Goto, J P O'Regan, H X Deng. Nature 1993
9

FDA-Approved Oligonucleotide Therapies in 2017.
Cy A Stein, Daniela Castanotto. Mol Ther 2017
327
8

Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.
Clotilde Lagier-Tourenne, Michael Baughn, Frank Rigo, Shuying Sun, Patrick Liu, Hai-Ri Li, Jie Jiang, Andrew T Watt, Seung Chun, Melanie Katz,[...]. Proc Natl Acad Sci U S A 2013
366
8

A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy.
C L Lorson, E Hahnen, E J Androphy, B Wirth. Proc Natl Acad Sci U S A 1999
998
8

Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models.
Alex McCampbell, Tracy Cole, Amy J Wegener, Giulio S Tomassy, Amy Setnicka, Brandon J Farley, Kathleen M Schoch, Mariah L Hoye, Mark Shabsovich, Linhong Sun,[...]. J Clin Invest 2018
72
11

Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models.
Lauren R Moore, Gautam Rajpal, Ian T Dillingham, Maya Qutob, Kate G Blumenstein, Danielle Gattis, Gene Hung, Holly B Kordasiewicz, Henry L Paulson, Hayley S McLoughlin. Mol Ther Nucleic Acids 2017
61
11

Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
Jeffrey B Carroll, Simon C Warby, Amber L Southwell, Crystal N Doty, Sarah Greenlee, Niels Skotte, Gene Hung, C Frank Bennett, Susan M Freier, Michael R Hayden. Mol Ther 2011
173
7



Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion.
Dhruv Sareen, Jacqueline G O'Rourke, Pratap Meera, A K M G Muhammad, Sharday Grant, Megan Simpkinson, Shaughn Bell, Sharon Carmona, Loren Ornelas, Anais Sahabian,[...]. Sci Transl Med 2013
436
7

The C9orf72 repeat expansion disrupts nucleocytoplasmic transport.
Ke Zhang, Christopher J Donnelly, Aaron R Haeusler, Jonathan C Grima, James B Machamer, Peter Steinwald, Elizabeth L Daley, Sean J Miller, Kathleen M Cunningham, Svetlana Vidensky,[...]. Nature 2015
527
7

GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport.
Brian D Freibaum, Yubing Lu, Rodrigo Lopez-Gonzalez, Nam Chul Kim, Sandra Almeida, Kyung-Ha Lee, Nisha Badders, Marc Valentine, Bruce L Miller, Philip C Wong,[...]. Nature 2015
451
7

Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
Yimin Hua, Kentaro Sahashi, Frank Rigo, Gene Hung, Guy Horev, C Frank Bennett, Adrian R Krainer. Nature 2011
443
7

Antisense oligonucleotides: A primer.
Daniel R Scoles, Eric V Minikel, Stefan M Pulst. Neurol Genet 2019
45
15

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice.
Lodewijk J A Toonen, Frank Rigo, Haico van Attikum, Willeke M C van Roon-Mom. Mol Ther Nucleic Acids 2017
49
12


The chemical evolution of oligonucleotide therapies of clinical utility.
Anastasia Khvorova, Jonathan K Watts. Nat Biotechnol 2017
365
6



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.